[
1. S. Z. Szatmári and P. J. Whitehouse, Vinpocetine for cognitive impairment and dementia, Cochrane Database Syst. Rev. 1 (2003) CD003119; https://doi.org/10.1002/14651858.CD003119840698112535455
]Search in Google Scholar
[
2. M. Wang, L. Wang, J. Sun, L. Zhang, L. Zhao and X. Xiong, Simultaneous determination of vinpocetine and its major active metabolite apovincaminic acid in rats by UPLC-MS/MS and its appli cation to the brain tissue distribution, J. Chromatogr. Sci. 56(3) (2018) 225–232; https://doi.org/10.1093/chromsci/bmx10429206914
]Search in Google Scholar
[
3. P. Bönöczk, B. Gulyás, V. Adam-Vizi, A. Nemes, E. Kárpáti, B. Kiss, M. Kapás, C. Szántay, I. Koncz, T. Zelles and A. Vas, Role of sodium channel inhibition in neuroprotection: effect of vinpocetine, Brain Res. Bull. 53(3) (2000) 245–254; https://doi.org/10.1016/S0361-9230(00)00354-311113577
]Search in Google Scholar
[
4. I. T. Lott, K. Osann, E. Doran and L. Nelson, Down syndrome and Alzheimer disease – Response to donepezil, Arch. Neurol. 59(7) (2002) 1133–1136; https://doi.org/10.1001/archneur.59.7.113312117361
]Search in Google Scholar
[
5. G. Fabbrini, P. Barbanti, C. Aurilia, C. Pauletti, G. L. Lenzi and G. Meco, Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease, Neurol. Sci. 23(1) (2002) 41–43; https://doi.org/10.1007/s10072020002212111620
]Search in Google Scholar
[
6. H. Ogura, T. Kosasa, Y. Kuriya and Y. Yamanishi, Donepezil, a centrally acting acethylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats, Methods Find. Exp. Clin. Pharmacol. 22(2) (2000) 89–95; https://doi.org/10.1358/mf.2000.22.2.79607010849891
]Search in Google Scholar
[
7. D. R. Liston, J. A. Nielsen, A. Villalobos, D. Chapin, S. B. Jones, S. T. Hubbard, I. A. Shalaby, A. Ramirez, D. Nason and W. F. White, Pharmacology of selective acethylcholinesterase inhibitors: implications for use in Alzheimer’s disease, Eur. J. Pharmacol. 486(1) (2004) 9–17; https://doi.org/10.1016/j.ejphar.2003.11.08014751402
]Search in Google Scholar
[
8. A. Khateb, J. Amman, J. M. Annoni and K. Diserens, Cognition-enhancing effects of donepezil in traumatic brain injury, Eur. Neurol. 54(1) (2005) 39–45; https://doi.org/10.1159/00008771816118495
]Search in Google Scholar
[
9. M. Fujiki, H. Kobayashi, S. Uchida, R. Inoue and K. Ishii, Neuroprotective effect of donepezil, a nicotinic acethylcholine-receptor activator, on cerebral infarction in rats, Brain Res. 1043(1-2) (2005) 236–241; https://doi.org/10.1016/j.brainres.2005.02.06315862539
]Search in Google Scholar
[
10. S. Kotani, T. Yamauchi, T. Teramoto and H. Ogura, Donepezil, an acethylcholinesterase inhibitor, enhances adult hippocampal neurogenesis, Chem. Biol. Interact 175(1-3) (2008) 227–230; https://doi.org/10.1016/j.cbi.2008.04.00418501884
]Search in Google Scholar
[
11. K. J. Kwon, M. K. Kim, E. J. Lee, J. N. Kim, B. R. Choi, S. Y. Kim, K. S. Cho, J. S. Han, H. Y. Kim, C. Y. Shin and S. H. Han, Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia, J. Neurol. Sci. 347(1-2) (2014) 66–77; https://doi.org/10.1016/j.jns.2014.09.02125266713
]Search in Google Scholar
[
12. M. Pohanka, Inhibitors of acethylcholinesterase and butyrylcholinesterase meet immunity, Int. J. Mol. Sci. 15(6) (2014) 9809–9825; https://doi.org/10.3390/ijms15069809410012324893223
]Search in Google Scholar
[
13. C. Scali, F. Casamenti, A. Bellucci, C. Costagli, B. Schmidt and G. Pepeu, Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats, J. Neural Transm. 109 (2002) 1067–1080; https://doi.org/10.1007/s00702020009012111444
]Search in Google Scholar
[
14. G. A. Higgins, M. Enderlin, R. Fimbel, M. Haman, A. J. Grottick, M. Soriano, J. G. Richards, J. A. Kemp and R. Gill, Donepezil reverse a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischemia, Eur. J. Neurosci. 15(11) (2002) 1827–1840; https://doi.org/10.1046/j.1460-9568.2002.02018.x12081663
]Search in Google Scholar
[
15. W. J. Krall, J. J. Sramek and N. R. Cutler, Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease, Ann. Pharmacother. 33(4) (1999) 441–450; https://doi.org/10.1345/aph.1821110332536
]Search in Google Scholar
[
16. A. Nordberg and A.-L. Svenson, Cholinesterase inhibitors in the treatment of Alzheimer’s disease - A comparison of tolerability and pharmacology, Drug Safety 19 (1998) 465–480; https://doi.org/10.2165/00002018-199819060-000049880090
]Search in Google Scholar
[
17. C. Yuede, H. Dong and J. G. Csernansky, Anti-dementia drugs and hippocampal-dependent memory in rodents, Behav. Pharmacol. 18(5-6) (2007) 347–363; https://doi.org/10.1097/FBP.0b013e3282da278d266693417762506
]Search in Google Scholar
[
18. M. J. H. J. Dekker, J. C. Bouvy, D. O’Rourke, R. Thompson, A. Makady, P. Jonsson and C. C. Gispende Wied, Alignment of European regulatory and health technology assessments: A review of licensed products for Alzheimer’s disease, Front. Med. (Lausanne) 6 (2019) Article ID 73 (9 pages); https://doi:10.3389/fmed.2019.0007310.3389/fmed.2019.00073651592731134200
]Search in Google Scholar
[
19. V. J. DeNoble, S. J. Repetti, L. W. Gelpke, M. Wood and K. L. Keim, Vinpocetine: nootropic effects on scopolamine-induced and hypoxa-induced retrieval deficits of a step-through passive avoidance response in rats, Pharmacol. Biochem. Behav. 24(4) (1986) 1123–1128; https://doi.org/10.1016/0091-3057(86)90465-X3714768
]Search in Google Scholar
[
20. A. Nemes, L. Czibula, C. Szántay, A. Gere, B. Kiss, J. Laszy, I. Gyertyán, Z. Szombathelyi and C. Szántay, Synthesis and evaluation of 2’-hydroxyethyl trans-apovincaminate derivatives as anti-oxidant and cognitive enhancer agents, J. Med. Chem. 51(3) (2008) 479–486; https://doi.org/10.1021/jm070618k18183943
]Search in Google Scholar
[
21. J. Prickaerts, A. Sick, F. J. van der Staay, J. de Vente and A. Blokland, Dissociable effects of acethylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation, Psychopharmacology 177 (2005) 381–390; https://doi.org/10.1007/s00213-004-1967-715630588
]Search in Google Scholar
[
22. F. Jia, M. Kato, H. Dai, A. Xu, T. Okuda, E. Sakurai, N. Okamura, T. W. Lovenberg, A. Barbier, N. I. Carruthers, K. Linuma and K. Yanai, Effects of histamine H3 antagonists and donepezil on learning and mnemonic deficits induced by pentylentetrazol kindling in weanling mice, Neuro-pharmacology 50(4) (2006) 404–411; https://doi.org/10.1016/j.neuropharm.2005.09.01716310812
]Search in Google Scholar
[
23. V. J. DeNoble, Vinpocetine enhances retrieval of a step-through passive avoidance response in rats, Pharmacol. Biochem. Behav. 26(1) (1987) 183–186; https://doi.org/10.1016/0091-3057(87)90552-13562490
]Search in Google Scholar
[
24. D. Dimitrova and D. Getova-Spassova, Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia, Pharmacol. Sci. 101 (2006) 199–204; https://doi.org/10.1254/jphs.fpe05006x16861821
]Search in Google Scholar
[
25. D. P. Getova and D. D. Dimitrova, Effects of GABAB receptor antagonists CGP63360, CGP76290A and CGP76291A on learning and memory processes in rats, Centr. Eur. J. Med. 2(3) (2007) 280–293; https://doi.org/10.2478/s11536-007-0033-3
]Search in Google Scholar
[
26. L. V. Vasileva, D. P. Getova, N. D. Doncheva, A. S. Marchev and M. I. Georgiev, Beneficial effect of commercial Rhodiola extract in rats with scopolamine-induced memory impairment on active avoidance, J. Ethnopharmacol. 193 (2016) 586–591; https://doi.org/10.1016/j.jep.2016.10.01127720849
]Search in Google Scholar
[
27. J. A. Quillfeldt, Behavioral Methods to Study Learning and Memory in Rats, in Rodent Model as Tools in Ethical Biomedical Research (Eds. M. L. Andersen and S. Tufik), Springer Cham, Heidelberg 2016, pp. 101–136.10.1007/978-3-319-11578-8_17
]Search in Google Scholar
[
28. W. Froestl, A. Muhs and A. Pfeifer, Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors, J. Alzheimers Dis. 32(4) (2012) 793–887; https://doi.org/10.3233/JAD-2012-12118622886028
]Search in Google Scholar
[
29. N. A. Suliman, C. N. Mat Taib, M. A. Mohd Moklas, M. I. Adenan, M. T. Hidayat Baharuldin, R. Basir, Establishing natural nootropics: Recent molecular enhancement influenced by natural noo-tropic, Evid. Based Complement. Alternat. Med. 2016 (2016) Article ID 4391375 (12 pages); https://doi.org/10.1155/2016/4391375502147927656235
]Search in Google Scholar
[
30. J. Jakubík, L. Bačáková, E. E. El-Fakahany and S. Tuček, Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors, Mol. Pharmacol. 52(1) (1997) 172–179; https://doi.org/https://doi.org/10.1124/mol.52.1.17210.1124/mol.52.1.1729224827
]Search in Google Scholar
[
31. S. Deiana, B. Platt and G. Riedel, The cholinergic system and spatial learning, Behav. Brain Res. 221(2) (2011) 389–411; https://doi.org/10.1016/j.bbr.2010.11.03621108971
]Search in Google Scholar
[
32. J. Jia, C. Wei, W. Chen, L. Jia, A. Zhow, F. Wang, Y. Tang and L. Xu, Safety and efficacy of donepezil 10 mg/day in patients with mild to moderate Alzheimer’s disease, J. Alzheimers Dis. 74(1) (2020) 199–211; https://doi.org/10.3233/JAD-19094031985467
]Search in Google Scholar
[
33. S. A. Jacobson and M. N. Sabbagh, Donepezil: potential neuroprotective and disease-modifying effects, Expert Opin. Drug Metab. Toxicol. 4(10) (2008) 1363–1369; https://doi.org/10.1517/17425255.4.10.136318798705
]Search in Google Scholar
[
34. H. G. Kim, M. Moon, J. G. Choi, G. Park, A.-J. Kim, J. Hur, K.-T. Lee and M. S. Oh, Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo, Neurotoxicology 40 (2014) 23–32; https://doi.org/10.1016/j.neuro.2013.10.00424189446
]Search in Google Scholar
[
35. S. J. Colloby, P. J. Nathan, I. G. McKeith, G. Bakker, J. T. O’Brien, J.-P. Taylor, Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies, Brain Commun. 2(2) (2020) Article ID fcaa098 (12 pages); https://doi.org/10.1093/braincomms/fcaa098747569432954342
]Search in Google Scholar
[
36. S. A. Wazea, W. Wadie, A. K. Bahgat, H. S. El-Abhar, Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways. Sci. Rep. 8 (2018) Article ID 5110 (10 pages); https://doi.org/10.1038/s41598-018-23359-6586517829572553
]Search in Google Scholar
, 